“Melphalan/HDS delivered meaningful improvements ... In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is marketed under the trade name CHEMOSAT ...

Delcath Systems, Inc. , an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will participate in the CG Horizons ...

In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan ...

CID-103 is an anti-CD38 antibody with the potential to be a best-in-class treatment for a myriad ... entry of domestically produced injectable melphalan, which created pricing pressure throughout ...

The company is known for its proprietary products, including the HEPZATO KIT™ and CHEMOSAT® Hepatic Delivery System for Melphalan ... system is regulated as a Class III medical device and ...

BEIJING, CHINA / ACCESS Newswire / March 31, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company focused on developing and ...

Sanofi's Sarclisa has been an also-ran in the anti-CD38 antibody class behind Johnson & Johnson ... or bortezomib, melphalan, and prednisone for the transplant-ineligible group.

Delcath Systems, Inc. , an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of a comparative analysis from the ...